- Home
- GNLX vs SGMT Comparison
GNLX vs SGMT Comparison
Compare GNLX & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNLX | SGMT |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 204.2M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GNLX | SGMT |
|---|---|---|
| Price | $2.44 | $5.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $19.75 | ★ $27.00 |
| AVG Volume (30 Days) | 265.8K | ★ 810.1K |
| Earning Date | 03-27-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $1.73 |
| 52 Week High | $8.54 | $11.41 |
Technical Indicators
Market Signals| Indicator | GNLX | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 44.02 |
| Support Level | $2.31 | $5.31 |
| Resistance Level | $2.55 | $7.20 |
| Average True Range (ATR) | 0.18 | 0.50 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 15.26 | 26.77 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.